Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 836-844

  Choi, Keun Hwa ^a   Kim, Jong Eun ^a   Song, Nu Ry ^a   Son, Joe Eun ^a   Hwang, Mun Kyung ^a,b   Byun, Sanguine ^a,b   Kim, Jong Hun ^b   Lee, Ki Won ^b   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Atherosclerosis; Migration; Phosphoinositide 3 kinase; Piceatannol; Platelet derived growth factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PICEATANNOL; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; RESVERATROL; S6 KINASE; SEPHAROSE; SYNAPTOPHYSIN;

AORTA MEDIA; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INDUCING AGENTS; AORTA; BINDING, COMPETITIVE; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DRUG INTERACTIONS; ENZYME INHIBITORS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; STILBENES;

EID: 76749157890     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp359     Document Type: Article

References (28)

1. Fougerat A, Gayral S, Gourdy P, Schambourg A, Ruckle T, Schwarz MK et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008;117:1310-1317.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
4. Hur KY, Seo HJ, Kang ES, Kim SH, Song S, Kim EH et al. Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury. Eur J Pharmacol 2008;586:226-233.
5. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15:197-204.
6. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79-113.
7. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA et al. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002;283:354-363.
8. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Atertio Thromb Vasc Biol 2003;23:795-801.
9. Lee CK, Lee HM, Kim HJ, Park HJ, Won KJ, Roh HY et al. Syk contributes to PDGF-BB-mediated migration of rat aortic smooth muscle cells via MAPK pathways. Cardiovasc Res 2007;74:159-168.
10. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Picea-tannol inhibits TNF-induced NF-kB activation and NF-kB-mediated gene expression through suppression of IkBa kinase and p65 phosphorylation. J Immunol 2002;169:6490-6497.
11. Li J, Tang MS, Liu B, Shi X, Huang C. A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal C141 cells. Oncogene 2004;23:3932-3944.
12. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-Kinase: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675.
13. Renaud S, De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-1526.
14. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006;6:36-47.
15. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resvera-trol, a natural antioxidant derived from grapes. Cardiovasc Res 2000;47:549-555.
16. Ferrigni NR, McLaughlin JL, Powell RG, Smith CR Jr. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 1984;47:347-352.
17. Wolter F, Clausnitzer A, Akoglu B, Stein J. Piceatannol, a natural analog of resver-atrol, inhibits progression through the s phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002;132:298-302.
18. Iijima K, Yoshizumi M, Hashimoto M, Akishita M, Kozaki K, Ako J et al. Red wine polyphenols inhibit vascular smooth muscle cell migration through two distinct signaling pathways. Circulation 2002;105:2404-2410.
19. Oak MH, Bedoui JE, Madeira SVF, Chalupsky K, Schini-Kerth VB. Delphinidin and cyanidin inhibit PDGFAB-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J Pharmacol 2006;149: 283-290.
20. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008;658:68-94.
21. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1b1. Br J Cancer 2002;86:774-778.
22. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 2008;68:946-955.
23. Matsumoto T, Yokote K, Tamura K, Takemoto M, Ueno H, Saito Y et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999;274:13954-13960.
24. Cospedal R, Abedi H, Zachary I. Platelet-derived growth factor-BB (PDGF-BB) regulation of migration and focal adhesion kinase phosphorylation in rabbit aortic vascular smooth muscle cells: Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinases. Cardiovasc Res 1999;41:708-721.
25. Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-g reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008;117:1310-1317.
26. Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL. Inhibition of mast cell FceR1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 1994;269:29697-29703.
27. Kim JE, Kwon JY, Lee DE, Kang NJ, Heo YS, Lee KW et al. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 2009;77:412-421.
28. Kwon JY, Lee KW, Kim J-E, Jung SK, Kang NJ, Hwang MK et al. Delphinidin suppresses UVB-induced clooxygenases-2 expression through inhibition of MKK4 and PI-3K. Carcinogenesis 2009; doi:10.1093/carcin/bgp216. Published online ahead of print 23 September 2009.